About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group is dedicated to paediatric research. We are interested in rare respiratory and endocrinological diseases, and also in common paediatric problems such as normal growth, asthma, neonatal pathology and imaging diagnosis, as well as minority diseases. Our goal is to transfer the findings of clinical and genetic studies to the widespread clinical practice and the general population, with the long-term objective of obtaining better diagnoses, implementing better therapeutic practices and improving the health of children.
Our group is part of CIBERER (Biomedical Research Networking Centre on Rare Diseases) (CIBERER U712) and European Reference Networks (ERN) for rare diseases ERN LUNG and Endo-ERN.
PMID: 33510243 Journal: Scientific Reports Year: 2021 Reference: Sci Rep. 2021 Jan 28;11(1):2420. doi: 10.1038/s41598-021-81802-7. Impact factor: 4.38 Publication type: Paper in international publication Authors: Delgado, Ignacio, Fernandez de Gamarra-Oca, Lexuri, Zubiaurre-Elorza, Leire, Junque, Carme, Solana, Elisabeth, Soria-Pastor, Sara, Vazquez, Elida, Poca, Maria A, Ojeda, Natalia, Macaya, Alfons et al. DOI: 10.1038/s41598-021-81802-7
PMID: 33039313 Journal: Pediatrics and Neonatology Year: 2021 Reference: Pediatr Neonatol. 2021 Jan;62(1):113-114. doi: 10.1016/j.pedneo.2020.09.005. Epub 2020 Sep 19. Impact factor: 2.083 Publication type: Paper in international publication Authors: Fernandez-Garcia, Cristina, Montaner-Ramon, Alicia, Hernandez-Perez, Susana, Camba-Longueira, Fatima, Ribes-Bautista, Carmen, Frick, Marie Antoinette, Castillo-Salinas, Felix et al. DOI: 10.1016/j.pedneo.2020.09.005
PMID: 33477770 Journal: Healthcare Year: 2021 Reference: Healthcare (Basel). 2021 Jan 19;9(1). pii: healthcare9010096. doi: 10.3390/healthcare9010096. Impact factor: 2.645 Publication type: Paper in international publication Authors: Cartanya-Hueso, Aurea, Lidon-Moyano, Cristina, Cassanello, Pia, Diez-Izquierdo, Ana, Martin-Sanchez, Juan Carlos, Balaguer, Albert, Martinez-Sanchez, Jose M et al. DOI: 10.3390/healthcare9010096
PMID: 33029631 Journal: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Year: 2021 Reference: J Clin Endocrinol Metab. 2021 Jan 1;106(1):e152-e170. doi: 10.1210/clinem/dgaa711. Impact factor: 5.958 Publication type: Paper in international publication Authors: Garcia-Arumi, Elena, Blasco-Perez, Laura, Paramonov, Ida, Mogas, Eduard, Soler-Colomer, Laura, Yeste, Diego, Antolin, Maria, Jaimes, Nadya, Campos-Martorell, Ariadna, Clemente, Maria et al. DOI: 10.1210/clinem/dgaa711
The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.
Es va reconèixer la tasca de més de 70 professionals dedicades a aquesta malaltia pulmonar, tant assistencial com de recerca.
The two studies awarded has been the research for a the ciliary dyskinesia diagnosis led by the VHIR’s Growth and Development Group and the EPISCAN II, in which Dr. Miravitlles has participated.
